Corvus Pharmaceuticals, Inc. (CRVS) Covered Calls

You can sell covered calls on Corvus Pharmaceuticals, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CRVS (prices last updated Fri 4:16 PM ET):

Corvus Pharmaceuticals, Inc. (CRVS) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1.92 +0.19 1.92 2.00 359K - 0.1
Covered Calls For Corvus Pharmaceuticals, Inc. (CRVS)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
May 17 2 0.15 1.85 8.1% 197%
Jun 21 2 0.25 1.75 14.3% 104%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California.